Consistent with previous reports that primary resistance of HCC to sorafenib resulted from genetic heterogeneity, such as EGFR activation23, and HBV expression24, in our study, five HCC cell lines with different genetic backgrounds exhibited different sensitivities to sorafenib. This evidence concerns the gene EGFR and hepatocellular carcinoma.